STUDY OF THE IMPACT OF STRESS CONDITIONS ON THE STABILITY OF NAFITIFINE HYDROCHLORIDE IN A CREAM DOSAGE FORM AS PART OF THE DEVELOPMENT OF AN ANALYTICAL METHOD FOR IMPURITY CONTROL
DOI:
https://doi.org/10.11603/mcch.2410-681X.2025.i4.15922Keywords:
naftifine hydrochloride; stress studies; HPLC; related substances; cream.Abstract
Introduction. The stability of active pharmaceutical ingredients in dosage forms is a key determinant of their quality and safety throughout the shelf life. Stress testing enables identification of the most vulnerable degradation pathways and provides insight into impurity profiles formed under extreme storage conditions. The Aim of the Study. To evaluate the behavior of naftifine hydrochloride in cream formulations under the influence of various stress factors and to determine the characteristics of degradation products formed under different types of stress conditions. Research Methods. The study was performed using an Agilent 1200 liquid chromatograph equipped with a diode-array detector (DAD). Chromatographic data acquisition and integration were carried out using OpenLab software. The chromatographic columns Synergi Hydro-RP (250 × 4,6 mm, 4 μm) and Gemini C18 (50 × 4,6 mm, 3 μm) were purchased from Phenomenex. Reference standards of naftifine hydrochloride (purity ≥ 99 %, HPLC grade) were obtained from USP; cinnamaldehyde (CA) and N-methyl-1-naphthalenemethylamine hydrochloride (purity ≥ 99 %, HPLC grade) were purchased from Sigma-Aldrich Chemicals Co. Commercial medicinal products included Esthesiphene® cream (Farmak JSC, Ukraine) and Exoderil® cream (Sandoz GmbH, Austria). Results and Discussion. Under most tested conditions – including acidic, alkaline, thermal, and light exposure – the chromatographic profiles remained largely unchanged, indicating good chemical stability of naftifine in the studied cream matrices. Marked changes were observed only under oxidizing conditions: new peaks appeared on the chromatograms, the intensity of several impurities increased substantially, and a distinct oxidative degradation pattern was formed, accompanied by a measurable decrease in the content of the active substance. High peak purity values and an acceptable mass balance confirmed the reliability of the detected changes and ensured confident discrimination between degradation products and matrix-related components. Conclusions. The study demonstrated that naftifine hydrochloride in cream formulations remains stable when exposed to acidic, alkaline, thermal, and photolytic conditions, whereas oxidizing conditions lead to significant degradation and the formation of specific oxidation products. These results highlight the susceptibility of the API to oxidation and provide important information for defining appropriate storage recommendations and supporting long-term stability assessment. The applied chromatographic method allowed the clear detection of impurity profile changes and is suitable for continued monitoring of degradation processes in further stability studies.
References
ICH. ICH Q1A (R2): Stability Testing of New Drug Substances and Products. Geneva : ICH, 2003. URL: https://database.ich.org/sites/default/files/ Q1A%28R2%29%20Guideline.pdf
ICH. ICH Q3B (R2): Impurities in New Drug Products. Geneva : ICH, 2006. URL: https://database.ich. org/sites/default/files/Q3B%28R2%29%20Guideline.pdf
Gupta A. K., Ryder J. E., Cooper E. A. Naftifine : a review. Journal of Cutaneous Medicine and Surgery. 2008.
PubChem – National Library of Medicine. URL: https://pubchem.ncbi.nlm.nih.gov/compound/5281098
Waterman K. C., Adami R. C. Accelerated aging: prediction of chemical stability of pharmaceuticals. International Journal of Pharmaceutics. 2005. Vol. 293. № № 1–2. P. 101–125.
Snyder R. L., Kirkland J. J., Dolan J. W. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken : John Wiley & Sons, 2009.
ICH. ICH Q2(R2): Validation of Analytical Procedures: Text and Methodology. Geneva : ICH, 2023.
Carstensen J. T., Rhodes C. T. Drug Stability: Principles and Practices. 4th ed. New York : CRC Press, 2000.
Shinde K. S., Jangme C. M., Patil A. R. RP-HPLC method for quantitative estimation of naftifine hydrochloride in formulated products. Journal of Applied Pharmaceutical Research. 2025. Vol. 13. № 4. P. 177–186.
Patel K. K. A. Validated RP-HPLC method for determination of terbinafine hydrochloride in pharmaceutical solid dosage form. International Journal of Pharmaceutical Technology. 2012. Vol. 4. P. 4663–4669.
Patel M. M., Patel H. D. Development and validation of RP-HPLC method for simultaneous estimation of terbinafine hydrochloride and mometasone furoate in combined dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2014. Vol. 6. P. 106–109.
Matysová L., Solich P., Marek P., Havlíková L., Nováková L., Sícha J. Separation and determination of terbinafine and its four impurities of similar structure using simple RP-HPLC method. Talanta. 2006. Vol. 68. P. 713–720.
European Directorate for the Quality of Medicines & HealthCare. European Pharmacopoeia. 11th ed. Strasbourg : EDQM, 2024. URL: https://www.edqm.eu/ en/european-pharmacopoeia-ph.-eur.-11th-edition
United States Pharmacopeial Convention. The United States Pharmacopeia. The National Formulary. Rockville, MD : USP, 2024. URL: https://www.uspnf.com
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. 2015 ed. Beijing : China Medical Science Press, 2015.
Farmak JSC. Estezifin® 1 % Cream. Package Insert. Kyiv : Farmak, n.d. URL: https://tabletki.ua/uk/%D 0%AD%D1%81%D1%82%D0%B5%D0%B7%D0%B8% D1%84%D0%B8%D0%BD/34489/
Center for Drug Evaluation and Research. Pharmacology/Toxicology NDA Review and Evaluation. Application № 204286 / 204286Orig1s000. U.S. Food and Drug Administration, n.d.
Естезифін® 1 % крем. Інструкція для медичного застосування. Київ : АТ «Фармак». URL: https://tabletki.ua/uk/%D0%AD%D1%81%D1%8 2%D0%B5%D0%B7%D0%B8%D1%84%D0%B8%D0 %BD/34489/
Екзодерил® 1 % крем. Інструкція для медичного застосування. Австрія : Sandoz GmbH, URL: https://tabletki.ua/uk/%D0%AD%D0%BA%D0%B 7%D0%BE%D0%B4%D0%B5%D1%80%D0%B8%D0 %BB/16326
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Medical and Clinical Chemistry

This work is licensed under a Creative Commons Attribution 4.0 International License.